Introduction {#S1}
============

Head and neck cancer is the sixth most common cancer worldwide with squamous cell carcinoma (SCC) representing over 90% of all histologies ([@B1]). Although cure can be achieved in over 80% of those who present with early stage disease, the majority of patients are diagnosed with locally advanced disease, where 5-year overall survival has plateaued around 50% over the last few decades ([@B1]). In an effort to improve cure rates, identification of a biomarker that detects cancer at an earlier stage would be a useful screening/diagnostic tool. Thus far, no such diagnostic tool exists.

MicroRNAs (miRNAs) are small (19--25 nucleotides) non-coding RNA molecules that regulate gene expression through complementary binding to a part of their target messenger RNA sequence, degrading it or inhibiting its translation ([@B2]). Thousands of miRNAs have been reported to date, and it has been estimated that approximately 30% of all genes are regulated by at least one miRNA ([@B3]). Mutation or dysregulation in the expression of miRNA results in a gain or loss of its function, leading to downregulation or upregulation of the target protein, and functioning as oncogenes or tumor suppressor genes ([@B4]).

MicroRNAs have been extensively studied over the last few years as potential biomarkers for screening and diagnosis of cancer. Multiple studies have analyzed the miRNA expression of head and neck cancers in an attempt to identify those with diagnostic, predictive and prognostic information ([@B5]--[@B7]). Results and interpretation of these studies have been complicated by the heterogeneous group of patients, the technique utilized, and the tissue analyzed (cell lines, tumor tissue, and blood). Furthermore, lack of comparison to age, sex, matched control, the different risk factors (HPV, tobacco, and alcohol) and how they affect miRNA expression, add to the complexity of interpreting these results.

In an attempt to better define the field, we analyzed the miRNA expression of plasma, tumor and matched benign tissue of oral tongue SCC patients.

Materials and Methods {#S2}
=====================

Patient and Tumor Characteristics {#S2-1}
---------------------------------

Newly diagnosed head and neck SCC patients, stages I--IV, naïve of treatment, were eligible to participate in this study. For homogeneity, only patients with oral tongue SCC undergoing surgery were analyzed here. Plasma samples of newly diagnosed tongue SCC patients were collected in EDTA tubes prior to surgery for extraction and analyses of circulating free and exosomal miRNA. Tumor and matched benign formalin-fixed in paraffin-embedded (FFPE) tissue blocks were selected from surgical resection specimens for miRNA extraction and analyses. All tumors were located in the oral tongue (anterior two-thirds) and showed morphologic features of conventional (i.e., keratinizing) SCC. Patients younger than 18 years old or with a history of metachronous or synchronous cancers were excluded. Clinical and tumor characteristics collected included age, sex, site and stage of disease, and alcohol and tobacco history. Tobacco users were defined as active, former, or never smokers. This study was approved by our institutional review board, and all patients provided written informed consent prior to tissue collection (protocol number 09-472).

Isolation of Total RNA from Paraffin-Embedded Tissue, Plasma, and Exosomes and RNA Quantitation {#S2-2}
-----------------------------------------------------------------------------------------------

H&E stains were prepared on 4 µm sections from the FFPE tissue blocks. Pathology review was undertaken to identify tumor and benign regions of interest (ROIs). Coring tools of 0.6 mm diameter were used to punch the ROI for subsequent RNA isolation. We implemented the Qiagen AllPrep DNA/RNA FFPE Kit (Qiagen, USA---cat\# 80234) following the manual's instructions for RNA extraction. TRIzol Reagent (Life Technologies, Inc., USA---cat\# 15596-026) was utilized in the isolation of RNA from the matched plasma specimens, as per the manufacturer's instructions. Exosomes were isolated with the ExoQuick serum exosome precipitation solution (Systems Biosciences, Inc., USA---cat\# EXOQ5A-1) with the addition of pacific hemostasis thromboplastin D to remove coagulating material, as per the manufacturer's instructions. The exosome solution was then subjected to TRIzol RNA isolation, as described for plasma. RNA isolates were quantified utilizing the Quant-iT RiboGreen assay (Life Technologies, Inc., USA---cat\# R11490) over the concentration range 1--100 ng/µl.

TaqMan-Based miRNA Profiling {#S2-3}
----------------------------

The TaqMan^®^ Array Human miRNA platform was chosen to quantitate the miRNA expression in the series of matched samples from patients. Prior to analysis, all the RNA samples were assessed for quality assurance and concentration using the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). The human 384-well TaqMan Array microfluidic two card set v3.0 (Array A and Array B, catalog no. 4444913, Life Technologies, Inc., USA) quantitates the expression of 747 unique and mature human miRNAs based on miRBase v20 ([@B8]). We determined that 60 ng of total RNA was the optimal input per sample per TaqMan array using the standard manufacturer's recommended protocol. The plasma and exosomal samples produced much lower yields with RNA concentrations at about 1 ng/µl each. For these samples, approximately 3 ng of input RNA was used per RT reaction using the manufacturer's protocol. Subsequently, a modified limited RNA protocol was used for the low RNA input samples. Twice the amount of cDNA product was added per preamplification reaction with thermal cycling at 95°C/10 min, 55°C/2 min, 72°C/2 min then 16 cycles of 95°C/15 s, 60°C/4 min followed by 99.9°C/10 min and 4°C on hold. The preamplified product was added undiluted to the final qPCR solution (1/100 of the total volume) and loaded on the TaqMan arrays. Standard recommended thermal cycling conditions were used for all the microfluidic cards to perform real-time PCR on a 7900HT Real-Time PCR system (Life Technologies, Inc., USA).

Statistical Analysis {#S2-4}
--------------------

The comparative Cq method was utilized to assess the results of the miRNA profiling experiment. Initially we focused on determining the miRNAs that were differentially expressed between the tumors and the matched benign tissue. We filtered the data to exclude miRNAs that were expressed in less than 50% of the samples. If both the tumor and benign tissue had an average miRNA expression level \>35 Cq units, the miRNAs were also excluded from the subsequent analysis. We calculated the mean miRNA expression for all miRNAs for a given sample and utilized this global mean value to determine the ΔCq value ([@B9]). We calculated log~2~ of the fold change to assess the differential expression between the tumor and benign ROIs. We then conducted Student's *t*-test to determine statistical significance between the tumor and benign sample groups. *p*-Values \< 0.05 were considered statistically significant. We calculated adjusted *p*-values based on the Benjamini--Hochberg test to stringently identify statistically significant differences between the tumor and benign tissues. Adjusted *p*-values \< 0.05 were considered statistically significant.

Results {#S3}
=======

Five patients with AJCC Stage II--IVa oral tongue conventional SCC were analyzed (Table [1](#T1){ref-type="table"}). Sixteen of 359 miRNAs detected were differentially expressed between tumor and matched benign tissue (adjusted *p* \< 0.05): 9 were upregulated (hsa-miR-19a; hsa-miR-512-3p; hsa-miR-27b; hsa-miR-20a; hsa-miR-28-3p; hsa-miR-200c; hsa-miR-151-3p; hsa-miR-223; hsa-miR-20b), and 7 downregulated (hsa-miR-22; hsa-miR-516-3p; hsa-miR-370; hsa-miR-139-5p; hsa-let-7e; hsa-miR-145-3p; hsa-miR-30c) in tumor tissue in comparison to matched benign tissue (Table [2](#T2){ref-type="table"}). All nine upregulated tumor-tissue miRNAs were expressed in both tumor and plasma (both free and within exosomes), except for hsa-miR-512-3p, which was only present in tumor and within exosomes. Of the seven tumor-tissue miRNAs downregulated, four (hsa-miR-370; hsa-miR-139-5p; hsa-miR-let-7e; hsa-miR30c) were expressed in both tumor and plasma (both free and within exosomes); hsa-miR-516-3p was present in tumor only, and hsa-miR-22 and hsa-miR-145-3p were present in tumor and exosome only.

###### 

Patients' characteristics.

  Patient   Site of disease   Stage   Age   Sex      Alcohol use   Tobacco use
  --------- ----------------- ------- ----- -------- ------------- -------------
  P96       Oral tongue       T3N2b   68    Male     Active        Former
  P103      Oral tongue       T2N0    68    Female   Active        Never
  P114      Oral tongue       T2N1    39    Male     Active        Never
  P35       Oral tongue       T3N2c   55    Female   Active        Active
  P41       Oral tongue       T2N0    55    Male     Active        Active

###### 

Adjusted *p*-value and log~2~ fold change of tumor versus benign tissue microRNA (miRNA) expression.

  miRNA            miRBase accession number[^a^](#tfn1){ref-type="table-fn"}   Benjamini--Hochberg adjusted *p*-value   log~2~ FC
  ---------------- ----------------------------------------------------------- ---------------------------------------- -----------
  hsa-miR-19a      MIMAT0000073                                                0.0036                                   0.32
  hsa-miR-512-3p   MIMAT0002823                                                0.0083                                   0.41
  hsa-miR-27b      MIMAT0000419                                                0.0101                                   0.47
  hsa-miR-20a      MIMAT0000075                                                0.0111                                   0.31
  hsa-miR-28-3p    MIMAT0004502                                                0.0135                                   0.40
  hsa-miR-200c     MIMAT0000617                                                0.0138                                   0.29
  hsa-miR-151-3p   MIMAT0000757                                                0.0176                                   0.31
  hsa-miR-223      MIMAT0000280                                                0.0355                                   0.28
  hsa-miR-20b      MIMAT0001413                                                0.0395                                   0.34
  hsa-miR-22       MIMAT0000077                                                0.0027                                   −0.35
  hsa-miR-516-3p   MIMAT0006778-MIMAT0002860                                   0.0096                                   −0.37
  hsa-miR-370      MIMAT0000722                                                0.0111                                   −0.34
  hsa-miR-139-5p   MIMAT0000250                                                0.0120                                   −0.37
  hsa-let-7e       MIMAT0000066                                                0.0120                                   −0.42
  hsa-miR-145-3p   MIMAT0004601                                                0.0300                                   −0.34
  hsa-miR-30c      MIMAT0000244                                                0.0347                                   −0.35

*^a^Based on miRBase v21*.

Discussion {#S4}
==========

To the best of our knowledge, this is the first study comparing the expression pattern of miRNA in tongue SCC, matched benign tissue and plasma (both free and within exosomes) of the same patients in an attempt to identify a signature pattern of miRNAs that would serve as a "liquid biopsy" for this patient population. All nine upregulated and six of the seven downregulated miRNAs in tumor compared to matched benign tissue were present in the circulating exosomes. Tumor cells may utilize exosomes to transport oncoMirs to other sites, leading to uncontrolled proliferation of cells away from the primary site (metastasis). Similarly, tumor cells may remain in a proliferative state by eliminating tumor suppressor-miRNAs from their environment. Indeed, eight of the upregulated and five of the downregulated miRNAs have been previously demonstrated to also be overexpressed and suppressed in other malignancies, reinforcing their role as oncogenes and tumor suppressor genes, respectively (Table [3](#T3){ref-type="table"}).

###### 

MicroRNAs (miRNAs) that pass stringent criteria for significance and fold change between tumor cells and matched benign tissue with its expression sites and whether previous association with cancer has been reported.

  miRNA            Expression     Cancer association (Y/N)   Upregulated (Y/N)
  ---------------- -------------- -------------------------- -----------------------------------
  hsa-miR-19a      Common         Y                          Y ([@B10])
  hsa-miR-512-3p   T and E only   Y                          N ([@B11])
  hsa-miR-27b      Common         Y                          Y ([@B12]) and N ([@B13])
  hsa-miR-20a      Common         Y                          Y ([@B14])
  hsa-miR-28-3p    Common         Y                          Y ([@B15])
  hsa-miR-200c     Common         Y                          Y ([@B16]) and N ([@B17])
  hsa-miR-151-3p   Common         Y                          Y ([@B18])
  hsa-miR-223      Common         Y                          Y ([@B19]) and N ([@B15])
  hsa-miR-20b      Common         Y                          Y ([@B20])
  hsa-miR-22       T and E only   Y                          Y ([@B19], [@B21]) and N ([@B22])
  hsa-miR-516-3p   T only         N                          N/A
  hsa-miR-370      Common         Y                          Y ([@B23])
  hsa-miR-139-5p   Common         Y                          N ([@B24])
  hsa-let-7e       Common         Y                          N ([@B25])
  hsa-miR-145-3p   T and E only   Y                          N ([@B26])
  hsa-miR-30c      Common         Y                          N ([@B27])

*T, tumor; E, exosome*.

*Common: tumor, exosome, and plasma. Purple: upregulated miRNAs. Green: downregulated miRNAs*.

Wong et al. performed a study comparing the miRNA expression pattern of tongue cancer cells and their paired normal cells in 4 patients with tongue cancer and nodal metastasis ([@B7]). Of the 156 miRNAs tested, 24 were at least 3-fold upregulated, and 13 downregulated in tumor cells in comparison to the normal cells. miRNA-184 was 59-fold higher in tumor cells in comparison to control cells, and when tested in the plasma was detected in 24 of 30 (80%) cancer patients in comparison to 5 of 38 (13%) normal individuals ([@B7]). Zhou et al. identified 25 differentially expressed miRNAs (21 overexpressed and 4 underexpressed; fold change \>2; *p* \< 0.01) between 15 tongue SCC patients and 3 normal controls. miR-424, miR-542-3p, and miR-454 were the most upregulated, and miR-494, miR-490-5p, and miR-486-5p were the most downregulated miRNAs in tumor in comparison to the normal tissue ([@B28]).

Boldrup et al. analyzed the expression of three miRNAs in different oral cavity subsites and highlighted the importance of taking the subsite of tumors into consideration when analyzing oral cavity SCC ([@B29]). In their study, miRNA-21 was significantly upregulated, and miRNA-125b and miRNA-203 were significantly downregulated in tongue SCC compared with clinically normal tissue adjacent to the tumors, and that pattern differed between the other oral cavity subsites analyzed ([@B29]). In a different study, Boldrup et al. evaluated the expression of miRNA-424 in tongue SCC, its adjacent clinically normal tongue and in tongue tissue of healthy individuals ([@B30]). Blood samples of some of the patients prior to surgery and of healthy individuals were also collected. miRNA-424 expression was highest in tongue SCC, followed by normal tissue of healthy individuals, and lowest in clinically normal tissue adjacent to the tumor. The authors suggested that this may have been due to the lack of normal regulation in tumor tissue. In addition, this miRNA was variably detected in plasma at very low levels with no significant difference between cancer patients and healthy individuals, suggesting that circulating miRNA-424 was not an ideal biomarker for early tongue cancer detection.

Currently, there has not been a consensus among different studies of the differentially expressed miRNAs between tumor and matched normal tissues. The small number of patients, different techniques utilized, including the miRNA platform tested, may explain some of those differences. In addition, it is unclear whether and how patient's characteristics like sex, comorbidities, including immune status, social habits and age affect the miRNA expression pattern. Furthermore, overexpression (or upregulation) and underexpression (or downregulation) of a miRNA do not necessarily mean that miRNA function as an oncogene or tumor suppressor gene, respectively.

Arroyo et al. demonstrated that the large majority of circulating miRNAs travel in a non-membrane-bound form consistent with a ribonucleoprotein complex, while the minority travels within microvesicles and exosomes ([@B31]). Exosomes are 50--90 nm membrane-bound vesicles arising from multivesicular bodies and released from cells to the circulation by exocytosis ([@B32]). It is thought to be one the mechanisms of cell to cell communication. Whether traveling within vesicles or associated with the Argonaute2 (the effector component of the miRNA-induced silencing complex), circulating miRNAs are protected against the activity of the RNAses in the blood. Our study revealed that all upregulated, and six of the seven (86%) downregulated tumor-tissue miRNAs were seen within the circulating exosomes, suggesting that it may be a better method of detection of tumor-related miRNAs than those circulating vesicle-free in the plasma. If the minority of circulating miRNAs is within exosomes, and cancer cells are known to significantly increase the number of circulating exosomes, one may hypothesize that the majority of exosomal miRNA may indeed be tumor related.

Our study was limited by the small sample size, lack of a matched, cancer-free control group and serial circulating miRNA samples post cancer treatment.

Conclusion {#S5}
==========

We identified an aberrantly expressed pattern of miRNAs in both tumor and plasma of patients with tongue SCC relative to matched benign tissue. In addition, the exosomal-miRNA expression pattern matched tumor miRNA more reliably than circulating free miRNA, suggesting analysis of exosomes may be a better method for prediction of tumor-miRNA expression. Whether this exosomal-miRNA expression pattern can be used as a surrogate marker for tongue SCC is unclear at this time. Further studies with a larger cohort of patients are needed to validate our findings, and serial plasma samples will be required to determine whether this method has a role to evaluate treatment response/early recurrences.
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